Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2006 Mar 15;11(8):879–886. doi: 10.1016/0192-0561(89)90109-4

Muramyl peptides confer hepatoprotection against murine viral hepatitis

KNoel Masihi ∗, Hans Kröger ∗, Werner Lange ∗, Louis Chedid †
PMCID: PMC7173131  PMID: 2559041

Abstract

The hepatoprotection induced by synthetic muramyl peptides was investigated using a model of lethal murine mouse hepatitis MHV-3 virus infection. MDP and a nonpyrogenic analog, Murametide, inhibited the steep elevation of serum transaminases induced by MHV-3 irrespective of whether the immunomodulators were administered before or after the infection. A significant proportion of MDP or Murametide-treated animals, in contrast to controls, survived the MHV-3 infection. The histopathological examination of the liver revealed marked necrosis of the hepatic parenchymal cells and infiltration of the inflammatory cells in controls but not in MDP-treated animals.

References

  1. Bergmeyer H.U. Vol. 1. Verlag Chemie; Weinheim: 1974. p. 491. (Methoden der Enzymatischen Analyse). [Google Scholar]
  2. Blobel G., Potter V.R. Nuclei from rat liver: isolation method that combines purity with high yield. Science. 1966;154:1662–1665. doi: 10.1126/science.154.3757.1662. [DOI] [PubMed] [Google Scholar]
  3. Chedid L. Stimulation of nonspecific host defence mechanisms against infections. In: Masihi K.N., Lange W., editors. Immunomodulators and Nonspecific Host Defence Mechanisms against Microbial Infections. Pergamon Press; Oxford: 1988. pp. 3–10. [Google Scholar]
  4. Dietrich F.X., Hochkeppel H.K., Lukas B. Enhancement of host resistance against virus infections by MTP-PE, a synthetic lipophilic muramyl peptide-1. Increased survival in mice and guinea pigs after single drug administration prior to infection, and the effect of MTP-PE on interferon levels in sera and lungs. Int. J. Immunopharmac. 1986;8:931–942. doi: 10.1016/0192-0561(86)90095-0. [DOI] [PubMed] [Google Scholar]
  5. Farghali H., Machková, Julis I., Buchar E., Janku I., M⇒ek K. Possible effects of muramyl dipeptide on liver cell membranes. Meth. Find. expl. clin. Pharmacol. 1986;8:131–136. [PubMed] [Google Scholar]
  6. Farghali H., Machková Z., Kameniková L., Janku I., M⇒ek K. The protection from hepatotoxicity of some compounds by the synthetic immunomodulator muramyl dipeptide (MDP) in rat hepatocytes and in vivo. Meth. Find. expl clin. Pharmacol. 1984;6:449–454. [PubMed] [Google Scholar]
  7. Fraser-Smith E.B., Waters R.V., Matthews T.R. Correlation between in vivo anti-pseudomonas and anti-candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice. Infect. Immun. 1982;35:105–110. doi: 10.1128/iai.35.1.105-110.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. George C.X., Jain R.K., Gupta C.M., Anand Enhancement in anti-Semliki Forest virus activity of ds RNA by muramyl dipeptide. Fed. Eur. Biochem. Soc. 1986;200:37–41. doi: 10.1016/0014-5793(86)80506-3. [DOI] [PubMed] [Google Scholar]
  9. Gledhill A.W., Bilbey D.L.J., Niven J.S. Effect of certain murine pathogens on phagocytic activity. Br. J. expl Path. 1965;46:433–442. [PMC free article] [PubMed] [Google Scholar]
  10. Ikeda S., Negishi T., Nishimura C. Enhancement of nonspecific resistance to viral infection by muramyldipeptide and its analogs. Antiviral Res. 1985;5:207–215. doi: 10.1016/0166-3542(85)90025-7. [DOI] [PubMed] [Google Scholar]
  11. Kidwell W.R., Burdette K.E. Poly (ADP-ribose) synthesis and cell division. Biochem. biophys. Res. Commun. 1974;61:766–773. doi: 10.1016/0006-291x(74)91023-7. [DOI] [PubMed] [Google Scholar]
  12. Koff W.C., Showalter S.D., Hampar B., Fidler I.J. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide. Science. 1985;228:495–497. doi: 10.1126/science.2984772. [DOI] [PubMed] [Google Scholar]
  13. Leclerc C., Chedid L. Macrophage activation by synthetic muramyl peptides. Lymphokines. 1982;7:1–21. [Google Scholar]
  14. Lefrancier P., Derrien M., Jamet X., Choay J., Lederer E., Audibert F., Parant M., Parant F., Chedid L. Apyrogenic adjuvant-active N-acetyl-muramyl dipeptides. J. med. Chem. 1982;25:87–90. doi: 10.1021/jm00343a018. [DOI] [PubMed] [Google Scholar]
  15. Masihi K.N., Brehmer W., Azuma I., Lange W., Müller S. Stimulation of chemiluminescence and resistance against aerogenic influenza virus infection by synthetic muramyl dipeptide combined with trehalose dimycolate. Infect Immun. 1984;43:233–237. doi: 10.1128/iai.43.1.233-237.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Masihi K.N., Brehmer W., Lange W., Ribi E. Effects of BCG, mycobacterial fractions and synthetic adjuvant (MDP) on the resistance of mice to aerogenic influenza virus infection. In: Preud' Homme J.L., Hawken J.A.L., editors. Abstracts 4th International Congress of Immunology. International Union of Immunological Societies; Paris: 1980. p. 11.8.18. [Google Scholar]
  17. Masihi K.N., Brehmer W., Lange W., Ribi E. Effects of mycobacterial fractions and muramyl dipeptide on the resistance of mice to aerogenic influenza virus infection. Int. J. Immunopharmac. 1980;5:403–410. doi: 10.1016/0192-0561(83)90015-2. [DOI] [PubMed] [Google Scholar]
  18. Masihi K.N., Brehmer W., Lange W., Ribi E., Schwartzman S. Protective effect of muramyl dipeptide analogs in combination with trehalose dimycolate against aerogenic influenza and Mycobacterium tuberculosis infections in mice. J. biol. Resp. Modif. 1984;3:663–671. [PubMed] [Google Scholar]
  19. Masihi K.N., Lange W., Rohde-Schulz B. Modulation of natural killer cytotoxicity by muramyl dipeptide and trehalose dimycolate incorporated in Squalane droplets. Cancer Immun. Immunother. 1987;24:19–24. doi: 10.1007/BF00199828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. McGlynn K.A., Lustbader E.D., London W.T. Immune responses to hepatitis B virus and tuberculosis infections in Southeast Asian refugees. Am. J. Epidemiol. 1985;122:1032–1036. doi: 10.1093/oxfordjournals.aje.a114184. [DOI] [PubMed] [Google Scholar]
  21. Sakuma T., Azuma M., Yoshida I. Effect of N-acetylmuramyl-L-alanyl-D-isoglutamine on interferon production in mice by Newcastle disease virus. J. genet. Virol. 1984;65:999–1003. doi: 10.1099/0022-1317-65-5-999. [DOI] [PubMed] [Google Scholar]
  22. Talmadge J.E., Schneider M., Collins M., Phillips H., Herberman R.B., Wiltrout R.H. Augmentation of NK cell activity to tissue specific sites by liposomes incorporating MTP-PE. J. Immun. 1985;135:1477–1483. [PubMed] [Google Scholar]
  23. Virelizier J.L. Role of macrophages and interferon in natural resistance to mouse hepatitis virus infection. In: Haller O., editor. Vol. 92. Springer-Verlag; Berlin: 1981. pp. 53–64. (Current Topics in Microbiology and Immunology). [DOI] [PubMed] [Google Scholar]
  24. Xu Z., Fidler I.J. The in situ activation of cytotoxic properties in murine kupfer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide. Cancer Immun. Immunother. 1984;18:118–122. doi: 10.1007/BF00205745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yamamura Y., Ishihara C., Hamada N., Yamamoto K., Azuma I. Experimental and clinical studies on the effects of synthetic muramyl dipeptide derivatives on viral and opportunistic infections. Meth. Find. expl Clin. Pharmacol. 1986;8:11–14. [PubMed] [Google Scholar]

Articles from International Journal of Immunopharmacology are provided here courtesy of Elsevier

RESOURCES